FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:924-926 August 26, 2004 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Leonard, M. B. PubMed Citation

Diagnostic and therapeutic guidelines used for children are commonly extrapolated from studies conducted in adults. There are potential dangers in assuming that children will have the same response to disease or therapy as adults, given important physiological differences. For example, it is reasonable to question whether glucocorticoid excess will have the same skeletal effects in adults as in a growing child. Glucocorticoids are thought to threaten bone health through a number of mechanisms.¹ They reduce bone formation by inhibiting the number and function of bone-building osteoblasts. Glucocorticoids also contribute to bone loss by stimulating calciuresis and impairing the intestinal absorption . . . [Full Text of this Article]

Source Information

From the Division of Pediatric Endocrinology, Stanford University Medical Center, Stanford, Calif.

This article has been cited by other articles:

• Chang, A. B., Glomb, W. B. (2006). Guidelines for Evaluating Chronic Cough in Pediatrics: ACCP Evidence-Based Clinical Practice Guidelines. Chest 129: 260S-283S [Abstract] [Full Text]  
• Rudge, S., Hailwood, S., Horne, A., Lucas, J., Wu, F., Cundy, T. (2005). Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology (Oxford) 44: 813-818 [Abstract] [Full Text]